cytotoxic chemotherapy

cytotoxic chemotherapy

chemotherapy designed to kill tumor cells.
References in periodicals archive ?
Analysis from business intelligence provider GBI Research - Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation - states that as the ovarian cancer therapeutics market becomes more diverse, it will become less reliant on indiscriminate and highly cytotoxic chemotherapy regimens.
Objective: The proposed research aims at discovering inhibitors of protein-protein interaction (PPI) between RAD51 and BRCA2 as a promising treatment of cancer, in particular to reverse the resistance of cancer cells to radiotherapy and cytotoxic chemotherapy.
We've had the combination of surgical management and cytotoxic chemotherapy for many years, but we haven't really seen anything else in terms of a fundamental class of treatment.
1 Aloxi(r) has been available in the USA since 2003, and is indicated in Australia for the management of nausea and vomiting associated with cytotoxic chemotherapy.
We examine recent landmark studies demonstrating metformin's ability to specifically target the cancer-initiating stem cells from which tumor cells develop, thereby preventing cancer relapse when used in combination with cytotoxic chemotherapy (dandelion hypothesis).
Moertel's patients and doctors hugely outnumber patients and doctors in alternative treatment, that means that most dying cancer patients in the US will continue to be subjected to cytotoxic chemotherapy if they insist on a treatment attempt.
Included are articles on screening, assessment of predictive markers, the use of cytotoxic chemotherapy and newer biological therapies, and multimodality management.
All told, 121 women received cytotoxic chemotherapy during pregnancy.
The median overall birth weight was 2,760 g for 121 newborns who were exposed, and 2,785 g for the 36 newborns who were not exposed to cytotoxic chemotherapy while in utero.
Zamoyski for cancer specific S-Phase enrichment relative to administrations of S-Phase cytotoxic chemotherapy.
The anti-VEGF monoclonal antibody, bevacizumab, increases the activity of a variety of active cytotoxic regimens and it has been shown in randomised Phase III trials that when combined with irinotecan plus 5-fluorouracil (5-FU) / leucovorin (LV) in the first-line treatment of metastatic CRC and with FOLFOX (5-FU/LV/oxaliplatin) in second-line treatment, leads to an increased median survival, progression-free survival (PFS) and response rate (RR) compared to the cytotoxic chemotherapy alone [3].

Full browser ?